Innovative diagnostic test for tuberculosis could save millions of lives

Lifearc® the medical research charity, and The University of St Andrews Infection Group today announced a partnership to develop a molecular diagnostic test...

LifeArc appoints Head of Seed Funds

David Holbrook has been appointed to manage our newly created Seed Fund. The £25m fund will invest in innovative early stage therapeutics and biological research aiming to deliver new treatments for patients.

CEO Dave Tapolczay stepping down

Dave Tapolczay, Chief Executive Officer, LifeArc, has announced his intention to step down after 10 years in…

LifeArc announces £5M support for rare disease research

LifeArc®, the medical research charity, today announced its Philanthropic Fund will award £5M in grants to support medical research projects focused on rare diseases.

New partnership in artificial intelligence and machine learning for target discovery announced

New LifeArc®/Milner Therapeutics Institute partnership use machine learning to identify and validate new drug targets in immuno-oncology and respiratory diseases.